Leonor Castro

Leonor Castro

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2026 in Methods
Verified
Journal Article
Open access
LCLeonor Castro
Leonor Castro
LPLara Paiva
Lara Paiva
ILInês Lobo
Inês Lobo
ANAna R. Neves
Ana R. Neves
TATânia Albuquerque
Tânia Albuquerque
Diana Barata CostaDiana Barata Costa
Diana Barata Costa
Glioblastoma (GB) is among the most aggressive and treatment-resistant cancers, highlighting the urgent need for physiologically relevant preclinical models. Traditional two-dimensional (2D) cultures fall short in replicating the complex microenvironment of GB, whereas three-dimensional (3D) culture models offer improved structural, biochemical, and functional resemblance to in vivo tumors. However, the lack of a standardized protocol for GB spheroid formation leads to significant inter-study variability and limited reproducibility. This review summarizes the key variables affecting spheroid generation, such as cell line selection, passage number, seeding density, matrix composition, and culture duration, and compares the effectiveness of commonly used methods like low-attachment plates, scaffold-based systems, and hydrogel embedding. Additionally, emerging trends in co-culture strategies and tumor microenvironment (TME) simulation are also highlighted. By outlining current strengths, limitations, and gaps, we provide a framework for advancing standardized, high-fidelity GB spheroid systems to accelerate translational research and therapeutic discovery.

Verified
Journal Article
Open access
PDF file
LCLeonor Castro
Leonor Castro
ANAna Raquel Neves
Ana Raquel Neves
EVEric Vives
Eric Vives
Prisca BoisguérinPrisca Boisguérin
Prisca Boisguérin
Ângela SousaÂngela Sousa
Ângela Sousa
Diana Barata CostaDiana Barata Costa
Diana Barata Costa
Glioblastoma (GB), the most prevalent and aggressive brain tumor, remains one of the most lethal challenges in modern oncology. Standard therapy remains largely ineffective, mainly due to limited therapeutic penetration across the blood–brain barrier (BBB) and adaptive tumor resistance. Consequently, there is an urgent need for innovative strategies to enhance therapeutic precision and efficacy. To address these limitations, we engineered a targeted peptide-based co-delivery system using the WRAP5 cell-penetrating peptide functionalized with a transferrin receptor (TfR)-targeting T7 peptide (sequence: HAIYPRH), enabling simultaneous delivery of temozolomide (TMZ) and a p53-encoding plasmid DNA. The resulting peptide-based TMZ/p53 nanocomplexes exhibited favorable physicochemical properties, enhanced TfR-mediated cellular uptake, and targeted antitumor activity mediated through p53-induced apoptosis in two-dimensional (2D) U87 MG cell cultures. To better reproduce the structural and cellular complexity of the tumor microenvironment, a three-dimensional U87 MG spheroid model was established and optimized using a Design of Experiments (DoE) approach to improve reproducibility and physiological relevance. The developed WRAP5-based nanocomplexes induced a significant dose-dependent inhibition of growth and morphological alterations in the U87 MG spheroid model, accompanied by deep penetration and cell death throughout the spheroid. Collectively, these findings highlight the potential of this targeted and tailored nanosystem to enhance cellular transfection, enable drug/gene co-delivery, restore p53 function, and promote apoptosis, representing a promising therapeutic strategy for GB treatment.